Endovascular therapy 24 to 96 hours after stroke doubled functional independence in Radiology study

Photo: Brain scan films. National Cancer Institute / Unsplash

1. Endovascular therapy 24 to 96 hours after stroke doubled functional independence in Radiology study

A 308-patient multicenter study pushes well past the standard 24-hour thrombectomy window.

In a study published Nov. 17 in Radiology, patients with large vessel occlusion treated with endovascular thrombectomy 24 to 96 hours after symptom onset reached functional independence (modified Rankin Scale 0 to 2) at 90 days in 50.7% of cases, versus 28.2% with best medical management, an adjusted odds ratio of 3.8 [1]. The analysis from eight Chinese stroke centers included 205 thrombectomy patients and 103 medically managed patients; symptomatic intracranial hemorrhage (5.9% vs. 2.9%) and 90-day mortality (11.2% vs. 13.6%) did not differ significantly, though any intracranial hemorrhage was more frequent after EVT (23.9% vs. 3.9%) [1]. An accompanying editorial by Eric Russell, MD, of Northwestern, stresses that rapid treatment remains critical and that randomized trials are needed to confirm the findings [1].

2. White House withdraws Heidi Overton's FDA commissioner nomination ahead of committee vote

The agency has now gone nearly seven months without a permanent leader.

The White House on Nov. 17 dropped the nomination of Dr. Heidi Overton, deputy director of the Domestic Policy Council, to lead the FDA, days before a scheduled Senate HELP Committee vote [2]. Her nomination had drawn opposition from Republican senators over her positions on abortion, vaccines and vaping; HELP Chair Bill Cassidy said anti-abortion senators had sought final assurances from the administration, which withdrew her rather than make those commitments [2]. Kyle Diamantas is leading the FDA on an acting basis since Marty Makary's resignation in April [2].

3. FDA grants accelerated approval to GSK's Nelkarmi for previously treated ALK-positive lung cancer

Approval came ten days ahead of the agency's target date.

The FDA on Nov. 17 granted accelerated approval to Nelkarmi (neladalkib) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer after alectinib, or after two or more ALK TKIs plus platinum chemotherapy [3]. In the single-arm ALKOVE-1 trial of 222 previously treated patients, the confirmed objective response rate was 49% in those whose only prior ALK TKI was alectinib and 32% in the more heavily pretreated group, with intracranial response rates of 55% and 26% respectively [3]. Hepatotoxicity was the most common reason for permanent discontinuation, which occurred in 5% of patients [3].

4. InnovAge pays $36 million to settle allegations it delayed specialist care for PACE enrollees

The Denver-based operator allegedly let specialist referrals sit for more than a year.

InnovAge Holding Corporation agreed to pay $36 million, about $25.7 million to the United States and $10.3 million to Colorado, California, New Mexico and Virginia, to resolve False Claims Act allegations announced by the Justice Department on Nov. 17 [4]. From May 2016 to October 2022, the government alleged, the Program of All-Inclusive Care for the Elderly operator failed in thousands of instances to promptly schedule oncology, cardiology, surgery and neurology referrals, and internal audits allegedly found many orders outstanding for more than a year [4]. Former employees Monita Poudyal and Karen Lapcewich brought the whistleblower suits and will share $4.5 million of the federal recovery; the claims are allegations only and there has been no determination of liability [4].

Digest references

  1. AuntMinnie (Will Morton), "EVT beats medical management up to 96 hours after stroke," Nov. 17, 2026, reporting on Yi T, Hong L, et al., Radiology, DOI 10.1148/radiol.253919. auntminnie.com

  2. ABC News, "Trump's pick Heidi Overton dropped as nominee for FDA commissioner," Nov. 17, 2026 (updated Nov. 18). abcnews.com

  3. GSK, "Nelkarmi (neladalkib) receives US FDA accelerated approval" (Form 6-K exhibit), Nov. 17, 2026. sec.gov

  4. U.S. Department of Justice, "PACE Organization InnovAge Agrees to Pay $36M to Resolve False Claims Act Allegations," Nov. 17, 2026. justice.gov

Katie Coffee

Professional photographer, Medical journalist, Business Development & Head of Marketing at Innovative Vascular Institute, from Louisiana, to Nashville. Medical PR

https://katiecoffeephoto.com
Previous
Previous

Boston Scientific's Obsidio embolic occluded all target vessels in 125-patient U.S. registry

Next
Next

Sirtex acquires FDA-cleared Hourglass vascular plug for peripheral embolization